Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

Exclusion Criteria

• •1. Subject has contraindication to having an MRI scan
• •2. Subject has central or ultra-central lung tumor that would receive SABR on this study, defined as a lesion located within 2 cm of the trachea and proximal bronchial tree
• •3. Subject has received cytotoxic chemotherapy or investigational agent within 2 weeks of SBRT
• •4. Subject has uncontrolled brain metastases, spinal cord compression, or leptomeningeal carcinomatosis
• •5. Subject has any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \> grade 2) from previous anti-cancer therapy
• •6. Subject has any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results
• •7. Subject has received prior radiation therapy that directly overlaps any radiation therapy given in this study
• •8. Subject has received radiation therapy that could lead to an unacceptably high risk of clinically significant normal tissue injury due to high cumulative normal tissue dose as determined by the investigator
• •9. Female subject who are pregnant or breastfeeding
• •10. Subject who has received vascular endothelial growth factor (VEGF) inhibitor such as bevacizumab within 4 weeks prior to study therapy or planned to receive it within 4 weeks after study therapy.